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We conclude that pHTh during apnoea in anaes- 
thetized humans is a good parameter to estimate real 
pH and to decide on termination of the apnoeic 
period due to acidosis. 
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Dear Editor 
Air filtration units 
Warburton et al. (1) have completed a very impor- 
tant study which has demonstrated that yet another 
product being marketed for house mite avoidance, 
has no demonstrable value on aeroallergen levels or 
indeed on symptoms of asthma. Such studies are of 
immense importance in providing objective infor- 
mation on which recommendations can be made to 
patients. At present, far too many house dust mite 
sensitive asthma sufferers are persuaded to buy 
domestic products purporting to reduce aeroallergen 
levels, and the medical profession are unable to 
provide clear cut information on their value or lack 
of it (2). 
In their discussion, Warburton et al. (1) have cast 
some doubt on our low volume personal air sampling 
technique for measuring domestic aeroallergen expo- 
sure. We would accept that there is currently no gold 
standard of actual aeroallergen exposure measure- 
ment. However, we do believe that our technique is 
of significant and proven value. The reason why 
Warburton and colleagues’ air sampling technique 
was unable to show any allergen in two-thirds of the 
samples collected was because they used very high 
volume sampling. This has the effect of cleaning the 
air with the very small quantities of allergen in the air 
being diluted by the vast volume of air sampled. Low 
volume sampling collects the allergen at a rate below 
which it is being generated, and there is infinitely less 
dilution. Furthermore, it is essential to use sonication 
to extract the allergen from the samples. Far from 
this having the effect of not reflecting airborne levels 
as suggested in the discussion of Warburton et al., it 
is far more likely to yield meaningful results, and has 
been validated in relation to sensitization (3). 
Obviously a great deal more work is required to 
optimize sampling techniques, but it would have been 
sensible for Warburton et al. to read our previous 
work in this area which has shown that high volume 
sampling is of limited or no value. 
Notwithstanding these comments, studies of aller- 
gen avoidance techniques are essential if we are to 
make meaningful progress on behalf of the very large 
number of allergic subjects who are desperately 
awaiting advice which might have therapeutic benefit. 
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Dear Editor 
Carbon dioxide laser bronchoscopy 
We were interested to read the report by Waller 
et al. (1) of their experiences of using laser broncho- 
scopy in the palliative treatment of 142 patients with 
tracheobronchial tumours. They achieved improve- 
ment in symptoms (predominantly dyspnoea, cough, 
stridor, and haemoptysis) in the great majority of 
their patients, with an acceptable risk of compli- 
cations, using a median of two procedures per patient 
(range l-11) requiring a median of 2 days of post- 
operative inpatient care (range 144) during a mean 
follow-up of 18.3 months. 
The majority of their patients had already been 
treated with external beam radiotherapy (XRT), but 
there is a need to compare endobronchial treatment 
